MarketsandMarkets Presents
Human Liver Models Market worth 2.56 Billion USD by 2022
https://www.marketsandmarkets.com/Market-Reports/human-liver-model-market171046468.html
The report "Human Liver Models Market by Drug Discovery Platform (Non-alcoholic Fatty Liver Organoids, Liver-on-a-chip, 2D Models, Animal Models, 3D Bioprinting), and Region (North America, Europe, Asia Pacific, Rest of the World) - Global Forecast to 2022", The global human liver models market is expected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6% during the forecast period (2017-2022). Browse: 7 market data tables 2 figures 37 pages And in-depth TOC on ͞Human Liver Models Market͟ Download The PDF Brochure@ https://www.marketsandmarkets.com/pdfdownload.asp?id=171046468
The global human liver models market was valued at USD 1.23 Billion in 2016 and is projected to reach USD 2.56 Billion by 2022, at a CAGR of 13.6% during the forecast period. Base year considered for the report is 2016 and the forecast period considered for this report is 2017–2022.
https://www.marketsandmarkets.com/Market-Reports/human-liver-model-market171046468.html
The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure. Talk to Our Research Experts@ https://www.marketsandmarkets.com/speaktoanalyst.asp?id=171046468
Animal models accounted for the largest share of the market in 2017 The human liver models market is segmented on the basis of type into liver organoids, liver-on-a-chip, 2D models, animal models, and 3D bioprinting. In 2017, the animal models segment accounted for the largest share of the global market. https://www.marketsandmarkets.com/Market-Reports/human-liver-model-market171046468.html
The growth in the biosimilars market is expected to boost the preclinical market as the development of biosimilars and biopharmaceuticals requires an understanding of the
mechanism of action, quantification of pharmacological effects, and interpretation of toxicological data.
Preclinical research also helps in securing a clear definition of targets. Moreover, as the patents for many blockbuster drugs are set to expire by 2020, the demand for biosimilars
and preclinical services is likely to increase. The rising demand for preclinical services, in turn is expected to drive the demand for animal models.
https://www.marketsandmarkets.com/Market-Reports/human-liver-model-market171046468.html
North America held the largest share of the market in 2017
In 2017, North America accounted for the largest share of the human liver models market, followed by Europe.
The market for human liver models in this region is driven by the presence of a well-
established life sciences industry, growing awareness about the organoids technology, favorable government initiatives, growing incidence of NAFLD, and unavailability of livers for transplantation, increased research spending, rising focus on tissue culture-based
clinical diagnostics, and the availability of skilled professionals.
The key players in the global human liver models market are Emulate (US), Ascendance Bio (US), HĂŹREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan). https://www.marketsandmarkets.com/Market-Reports/human-liver-model-market171046468.html
About MarketsandMarkets™ Marketsa dMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide co pa ies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach Marketsa dMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at Marketsa dMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. Marketsa dMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. Marketsa dMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. Marketsa dMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
https://www.marketsandmarkets.com/Market-Reports/human-liver-model-market171046468.html
Contact Us Mr. Rohan MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA : 1-888-600-6441 Email: sales@marketsandmarkets.com MarketsandMarkets Blog http://www.marketsandmarkets.com http://twitter.com/marketsmarkets http://www.linkedin.com/company/marketsandmarkets